Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R/InsR inhibitors.

CONCLUSIONS: We provide evidence that loss of E-cadherin hyperactivates the IGF1R pathway and increases sensitivity to IGF1R/InsR targeted therapy, thus identifying the IGF1R pathway as a potential novel target in E-cadherin deficient breast cancers.
PMID: 29941485 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - June 25, 2018 Category: Cancer & Oncology Authors: Nagle AM, Levine KM, Tasdemir N, Scott JA, Burlbaugh K, Kehm JW, Katz TA, Boone DN, Jacobsen BM, Atkinson JM, Oesterreich S, Lee AV Tags: Clin Cancer Res Source Type: research